key: cord-0901279-k81nzycx
authors: Alnajjar, Radwan; Mostafa, Ahmed; Kandeil, Ahmed; Al-Karmalawy, Ahmed A.
title: Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease
date: 2020-12-03
journal: Heliyon
DOI: 10.1016/j.heliyon.2020.e05641
sha: 020d0dce89fe3475e56a42dffa61476d1588c7f4
doc_id: 901279
cord_uid: k81nzycx

Drug repurposing is the most rapid and economic way nowadays to rapidly provide effective drugs for our pandemic coronavirus disease 2019 (COVID-19). It was a great debate about ARBs whether to be stopped or continued for patients using them especially at the beginning of the COVID-19 pandemic. In this study, we carried out a virtual screening for almost all members of ARBs (nine) against COVID-19 main protease. Molecular docking as one of the important computational techniques was performed in this work. Interestingly, the tested compounds showed variable binding affinities in the order of N3 inhibitor (10, docked) > Fimasartan (8) > Candesartan (2) > Olmesartan (7) > Azilsartan (9) > Eprosartan (5) > Valsartan (3) > Losartan (1) > Irbesartan (6) > Telmisartan (4). Moreover, Fimasartan (8), Candesartan (2), and Olmesartan (7) were additionally estimated through molecular dynamic simulations monitored via computing the binding free energy using MM-GBSA. The results are promising for rapidly repurposing such drugs (especially, Fimasartan (8) and Candesartan (2)) after further preclinical and clinical studies either alone or in combination with others for the treatment of COVID-19 virus especially known to cause vasodilatation (to prevent blood coagulation) and to reduce inflammation and fibrosis (to prevent pulmonary fibrosis), with well-known safety profiles. In vitro, the virtual findings were consistent with the experimental testing of four representative ARBs. Out of the tested compounds, Olmesartan (7) showed the most promising anti-SARS-CoV-2 activity (IC(50) = 1.808 μM, and CC(50) = 557.6 μM) with high selectivity index (308.4) against SARS-CoV-2 in Vero E6 cells. This work may clarify and approve not only the safety of ARBs used by a large group of patients worldwide but also their possible effectiveness against the COVID-19 virus either as a prophylactic or treatment option. It intended also to give a clear spot on the structure-activity relationship (SAR) required for the future design of new drugs targeting the newly emerged SARS-CoV-2 protease by medicinal chemists.

By December 2019, a novel coronavirus, SARS-CoV-2, has been detected initially in China. The virus outbreak took place first in Wuhan city and continued to spread worldwide [1] . The world's attention has focused on the world out of our sight of viruses like never before, especially by causing 32,952,046 total confirmed cases till 26 September 2020 including 996,276 confirmed deaths all over 215 countries, areas, or territories as published officially on the World Health Organization website [2] . Being highly contagious, it has widely spread to every corner of the world [3] .

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing severe respiratory syndrome in humans [4] . Its main protease (M pro , 3CL pro ) is approved to be an attractive drug target among coronaviruses, due to its very crucial role in controlling viral replication and transcription [5, 6, 7] .

One of the most important and recent approaches to investigate the activity of a drug is the simulating nature through computational structure-based drug discovery. In this process, computer software test compounds into the selected binding sites in three-dimensional models of the protein targets. The interaction between the tested compounds and the binding site can be quantified using physics-based equations to calculate their binding affinities. The best compounds then tested experimentally on animal models to ensure their real binding and to confirm their effectiveness (such as stopping viral infectivity) [8] .

Drug repurposing is the reuse of an existing drug for the treatment of a new disease that is outside the scope of the original intended or approved one [9] . It leads to fast drug reach at a lower cost and shorter time than de novo drug development [10, 11, 12] . The importance of drug repurposing is currently well-understood especially after the emergence of the pandemic COVID-19 [13, 14] . Drugs such as ivermectin, ribavirin, remdisivir, and sofosbuvir were tested in silico and in vitro for their potential as a treatment for COVID-19 [15] .

However, most of the COVID-19 patients belong to elder stages with cardiovascular comorbidities such as hypertension, coronary artery disease, heart failure, or chronic kidney disease [16, 17, 18] . One of the most important classes for the treatment of such diseases are angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) [16] .

Both ACEIs and ARBs have been approved to decrease the progression of pulmonary complications in susceptible patients and to decrease the risk of pneumonia [19] . Moreover, ARBs are known to antagonize the actions of angiotensin II by blocking AT1 receptors preventing vasoconstriction, apoptosis, and proinflammatory and fibrosis effects ( Figure 1 ) [20] .

Interestingly, Zhang et al. observed that hypertensive cases hospitalized with COVID-19, among them those treated with ACEI/ARB were at a lower observed risk of mortality compared with nonusers [21] . Furthermore, it was approved that COVID-19 patients were not affected by the use of the renin-angiotensin-aldosterone system (RAAS) inhibitors and so should not be stopped to prevent a progression of COVID-19 [22] .

Depending on the previously mentioned therapeutic effects of ARBs as vasodilators (to decrease the tendency for coagulation), antiapoptotic, anti-inflammatory, and antifibrotic (to decrease the tendency for pneumonia) caused by COVID-19, hoping to repurpose them effectively for the potential treatment of pandemic COVID-19 infection.

In this study, angiotensin receptor blocker (ARB) drugs ( Figure 2 ) were selected for molecular docking studies against M pro . Furthermore, molecular dynamic (MD) simulations were passed out on the best-docked drug-protein complexes to acquire more acceptance of the affinity between the ligands and the COVID-19 main protease active site in the frank solvent model for 150 ns to evaluate the stability of the ligands within the binding site of the protein. These ligand-protein complexes were follower to the Molecular Mechanics/Generalized Born and Surface Area (MM/GB-SA) calculations to evaluate the consistent relative binding free energies.

Both docking studies using MOE 2019 suite [23] and molecular dynamic simulation studies using the Desmond simulation package of Schr€ odinger LLC [24] were performed to examine and confirm the binding affinities and modes of the FDA approved ARB drugs against COVID-19 main protease. The co-crystallized inhibitor (N3) was used as a standard reference.

The tested drugs were obtained from the PubChem website. They were prepared according to the default method described before [25] . The database containing both the co-crystallized N3 inhibitor and the aforementioned drugs was formed and saved as an MDB file for docking.

The Protein Data Bank website was used to download the crystal structure of the main protease (M pro ) of SARS-CoV-2 (PDB code 6LU7) [26] . It was prepared following the same preparation steps described [25] .

At first, a validation process was done for the co-crystallized N3 and a valid behavior was confirmed by obtaining low RMSD values between the docked and co-crystallized ones [27, 28] .

Docking of the aforementioned database containing the nine tested ARBs and the co-crystallized inhibitor N3 was performed according to the previously discussed procedure [29] . The best-obtained poses were selected according to their scores, binding modes, and rmsd_refine values.

The Molecular dynamic simulations were performed using the Schr€ odinger LLC package [24] . The NPT ensemble (T ¼ 300 K and P ¼ 1 bar) was performed. The length of the simulation was 150 ns and the relaxation time for all selected poses was one ps. The force field parameters (OPLS3) were applied [30] . A cutoff radius of 9.0 Å in Coulomb interactions, and orthorhombic periodic box boundaries were set away from the protein atoms at 10 Å. The water molecules were described using TIP3P model [31, 32] . Salt concentration was applied using Desmond System builder [33] and adjusted to 0.15 M NaCl. The pressure control was performed with a coupling constant of 2.0 ps using the MartynaÀTuckermanÀKlein chain coupling scheme. The temperature control was applied through the Nos eÀHoover chain coupling scheme [34, 35] . All of the obtained data were analyzed and recorded according to the previously mentioned methods [36] .

To observing the interactions' influence in ligand-protein stability, Maestro software was used. The MM -GBSA was done to estimate ligand strain energies and the ligand binding free energies for docked molecules over the 150 ns period with thermal_mmgbsa.py python script delivered via Schrodinger which receipts a Desmond trajectory file, separates it into individual snapshots, runs the MMGBSA calculations on each frame, and yields the average calculated binding energy.

To assess the half-maximal cytotoxic concentration (CC 50 ), stock solutions of the tested ARBs were dissolved in 10 % DMSO in ddH 2 O and diluted further to the working solutions with DMEM. The cytotoxic activity was tested by applying the MTT method with minor modifications in VERO-E6 cells. Briefly, the cells were seeded in 96 well-plates and incubated at 37 C and 5% CO 2 for 24 h. After that, the cells were treated with different concentrations of the tested ARBs in triplicates. And then the total methodology was completed as previously mentioned in detail [37] . The concentration caused a 50% cytotoxicity (TC 50 ) was obtained by plotting the% cytotoxicity versus sample concentration [38] .

The IC 50 concentrations were determined as previously described [39] . Briefly, in 96-well tissue culture plates, 2.4Â10 4 Vero-E6 cells were distributed in each well and incubated overnight at a humidified 37 C incubator under 5% CO 2 condition. The cell monolayers were then washed once with 1x PBS and subjected to virus adsorption for 1 h at room temperature (RT). The cell monolayers were further overlaid with 50 μl of DMEM containing varying concentrations of the test ARBs.

Following incubation for 72 h, the cells were fixed for 20 min using 100 μl of 4% paraformaldehyde and stained using 0.1% crystal violet in distilled water for 15 min at RT. The crystal violet dye was then dissolved using 100 μl absolute methanol per well and the optical density of the color was measured using Anthos Zenyth 200rt plate reader at 570 nm. The IC 50 of the compound is that required to decrease the virus-induced cytopathic effect (CPE) by 50%, compared to the virus control.

The ligand-binding site of COVID-19 M pro is located in the groove between a Cys-His catalytic dyad. The COVID-19 virus M pro binding pocket is fitted with the N3 inhibitor composed of only one polypeptide and showing an asymmetric unit. Molecular docking of Losartan 1, Candesartan 2, Valsartan 3, Telmisartan 4, Eprosartan 5, Irbesartan 6, Olmesartan 7, Fimasartan 8, Azilsartan 9, and N3 10 into M pro active site was performed. Their binding strength order was: N3 inhibitor (10,

The selection of poses was done according to their better obtained binding scores and rmsd_refine values, especially most of them achieved very close binding modes compared to N3. The obtained scores, RMSD_Refine values, and interactions with M pro pocket amino acids are represented in Table 1 .

The docked N3 (10) inside the COVID-19 virus M pro pocket achieved a binding score of -10.16 kcal/mol beside the formation of four H-bonds with Asn142, Phe140, Gln189, and Cys145, and one H-pi bond with His41amino acids of protease. On the other hand, it was found that especially, Fimasartan (8), Candesartan (2), and Olmesartan (7) members of ARBs having very close binding modes relative to the N3 inhibitor.

Fimasartan (8) showed a binding score of -7.82 kcal/mol with the formation of five H-bonds with Gly143, Cys145, Asn142, and Met165, and one pi-H bond with Gln189 amino acids. Moreover, Candesartan (2) showed a binding score of -7.79 kcal/mol with the formation of three Hbonds with His163 and Glu166, one pi-H bond, and one H-pi bond with Gln189 amino acids. Furthermore, Olmesartan (7) showed a binding a S: the score of a compound placement inside the protein binding pocket. b RMSD_Refine: the root-mean-squared-deviation (RMSD) between the predicted pose and those of the crystal one (after and before refinement process, respectively).

R. Alnajjar et al. Heliyon 6 (2020) e05641 score of -7.67 kcal/mol with the formation of three H-bonds with Gly143, Cys145, and His41, one H-pi bond with His41, and one pi-H bond with Glu166 amino acids (Table 2) . To compare the binding modes of ARBs and N3 inhibitor against COVID-19 main protease, 3D representations and surface and maps for each studied pose were introduced. The docking information of all tested compounds is represented in the supplementary material.

Briefly, the docking results of ARB drugs to M pro of COVID-19 compared to its N3 inhibitor clarified greatly the binding modes of them. Some gave ideal binding modes indicating high affinity and predicted intrinsic activity as well.

Docking protocols are usually rapid and imprecise-however, docking deficiencies protein flexibility, which may broker with the accuracy Table 2 . The 3D binding interactions and the 3D positioning of the best-docked ARBs (8, 2, &7) and N3-binding pocket within COVID-19 main protease (PDB: 6LU7) compared to the N3 (Docked).

3D interaction 3D protein positioning

Fimasartan (8) Candesartan (2) Olmesartan (7) N3 (10) H-bonds are represented by red dashed lines while H-pi interactions by black dashed lines. of the consequential ligand-protein complexes. So, further computationally expensive but additional accurate molecular dynamic simulation techniques might improve a better complementary with docking. Generally, MD simulation is used to estimate the macromolecule manners, and it depends on traditional mechanics and using Newton's equation of motion to compute the speed of and position of each atom of the considered system. Thereby, MD performs a more intensive conformational examination than docking does, which gives a more accurate illustration of protein motion. Taking into attention, the stated facts, MD simulations were proceeded using the Desmond package on the ligandpotential complex to mimic the interaction of these drugs with COVID-19 main protease active site for 150 ns. Fimasartan (8), Candesartan (2) , and Olmesartan (7) compounds were further selected for MD simulations ( Figure 2 ).

RMSD values of Cα atoms for all the complexes were estimated concerning their initial structure, attempting to record the effect of the compounds on the conformational stability of 6LU7 during simulations, the results were plotted in (Figure 3 ) as a function of the simulations time. The Candesartan-6LU7 complex reach equilibrium since the start of the calculations around ten ns with side chains residuals fluctuate from time to time, even though the fluctuation was within 1 Å, where the Fimasartan-6LU7 complex was stable till 40 ns before it starts fluctuated at 40 ns till reach equilibrium again at 130 ns, this fluctuation is due to the movement of the unfolded side chain, where Ser1 break bond with The RMSD of a ligand that is aligned and measured just on its reference conformation within the active site was represented by plotting the RMSD of ligands as a function of simulation time (Figure 4) , Fimasartan (8) and Candesartan (2) move around 4 Å concerning their reference position within the active site before reach equilibrium at 50 ns.

Olmesartan (7) was unstable within the active site of the COVID-19 main protease the drug shifted around protein during whole trajectories before reaching equilibrium at around 110 ns and settle down at a new site which is 40 Å far away from its original location as it can be seen in Figure 5 . Moreover, Figure 6a, 6b, and 6c show the ligand-protein alignment during simulations time for Olmesartan-6LU7, Fimasartan-6LU7, and Candesartan-6LU7, respectively.

The active site contains the following polar amino acid threonine (Thr190), glutamine (Gln143, Gln189, and Gln192), nonpolar amino acid methionine (Met49, Met165) and leucine (Leu27, Leu50), positively charged amino acid histidine (His41), and negatively charged amino acid glutamic (Glu166). As it can be seen from Figure 7 and Figure 8 , which were generated with simulation interactions, diagram panel implemented in Maestro software, these histograms explain the contacts that occur during the simulations between ligands and protein.

In the case of Fimasartan (8), His41, Gln192, and Gly143 were able to hold down the hydrogen bonding contacts during 85 %, 65 %, and 52 % of the time, respectively. Water bridge hydrogen bonding where one water used as a bridge between ligand and protein was also formed with Glu166, Gln189, and Gly143 residuals and Fimasartan (8) , finally, only one hydrophobic interaction was formed with Met165 during 35 % of simulation time. Candesartan (2) formed a more but weaker hydrogen bonding the strongest interaction was with Gln189 which was 50 % of the time, where interactions with Asp187, Arg188, Gly143, Asn142, Cys145, and Ser144 were around 10-30 % of the time, which led to higher MM-GBSA binding energy (Table 3) , hydrophobic attractions were formed with His41, Leu27, and Met49 during 30 %, 18 %, and 16% of trajectories, respectively. A small and neglectable ionic interaction occurs with Asn142 and Glu166 less than 10 % of the time.

Olmesartan (7), on the other hand, was not stable within the active site, it was able to maintain hydrogen bond with the following residuals Asn51, Thr190, and Ala191 up to 110 ns before it lost these interactions, which led to moving out of the active site. Olmesartan later established a Figure 9 . Dose-response curves for the tested drugs in Vero-E6 cells. Various dilutions of the drugs were applied to the 90% confluent cell monolayers and assayed after 72 h to determine the CC 50 (half-maximal cytotoxic concentrations) or IC 50 (half-maximal inhibitory concentrations). Nonlinear regression analysis of GraphPad Prism software (version 5.01) was used to calculate CC 50 and IC 50 by plotting log inhibitor versus normalized response (variable slope). new hydrogen bonding with Lys12 and hydrophobic attraction with Tyr154.

To calculate the average binding energy for equilibrated MD trajectory, further analysis using 200 selected snapshots with a 50 ps interval. The equation used to calculate the binding energy:

where ΔE MM is the difference in minimized energies as following:

The difference in GBSA solvation energy of the complex and the sum of ligand and protein solvation energies is denoted by ΔG solv . Also, ΔG SA is the difference in surface area energy of the complex and the sum of protein and ligand.

The thermal_mmgbsa.py python script introduced by Schrodinger was used to calculate the average MM-GBSA binding energy which also generates Coulomb energy (Coulomb), covalent binding energy (Covalent), Van der Waals energy (vdW), lipophilic energy (Lipo), Generalized Born electrostatic solvation energy (Solv_GB), and Hydrogen-bonding energy (H-bond). All the obtained results are shown in Table 3 .

From the MM-GBSA results, the most favored binding energy was exhibited by Candesartan (2) with strong vdW interactions and lipophilic energy (Table 3 ). In contrast, unfavored Coulomb energy was exerted by Candesartan which may result from the repealing with Glu166.

To validate the docking results which ordered the ARBs according to their binding affinities in the order of N3 inhibitor (10, docked) > Fimasartan (8) > Candesartan (2) > Olmesartan (7) > Azilsartan (9) > Eprosartan (5) > Valsartan (3) > Losartan (1) > Irbesartan (6) > Telmisartan (4) and which were confirmed further by molecular dynamic simulations, CC 50 and IC 50 were determined for Candesartan Cilexetil (prodrug of 2), Olmesartan (7), Losartan (1), and Irbesartan (6) . All tested compounds showed high to moderate antiviral activity against SARS-CoV-2 ranging from 1.808 to 7.668 μM (Figure 9 ). Collectively, the in vitro results of the tested compounds confirmed greatly the aforementioned computational studies except for Candesartan Cilexetil which is the available prodrug form of Candesartan (2) -(inactive in vitro)-and which explains clearly its deviation from our previous order. Interestingly, Olmesartan (7) showed the best selectivity index (>300) against SARS-CoV-2 in VERO E6 cells (Table 4 ).

Nine ARB drugs widely used for the treatment of hypertension, coronary artery disease, heart failure, or kidney disease were subjected to molecular docking against COVID-19 main protease. The tested drugs exhibited variable degrees of affinities toward COVID-19 protease compared to N3 inhibitor in the order of N3 inhibitor (10, docked) > Fimasartan (8) > Candesartan (2) > Olmesartan (7) > Azilsartan (9) > Eprosartan (5) > Valsartan (3) > Losartan (1) > Irbesartan (6) > Telmisartan (4). The molecular dynamic simulations presented a moderate interaction between Fimasartan (8) and Candesartan (2) with the COVID-19 main protease with the latter being more favored; also, MD showed that Olmesartan (7) was not stable at all within the active site and left after 110 ns. The MM-GBSA binding energy showed that both Fimasartan (8) and Candesartan (2) had low binding energy compared to the N3 inhibitor by almost~-35 kcal/mol. In conclusion, it looks like-charged molecules are not favorable for the main protease active site of COVID-19. The CC 50 and IC 50 concentrations were determined for Candesartan Cilexetil (prodrug of 2), Olmesartan (7), Losartan (1), and Irbesartan (6) . All the tested compounds showed high to moderate antiviral activity against SARS-CoV-2 ranging from 1.808 to 7.668 μM. Interestingly, Olmesartan (7) showed the best CC 50 and IC 50 values (557.6 and 1.808 μM, respectively), and selectivity index (>300) against SARS-CoV-2 in VERO E6 cells. Finally, the present study confirmed the affinities of the tested ARB drugs against COVID-19 main protease. Such a drug especially, Fimasartan (8), Candesartan (2), and Olmesartan (7) members of ARBs are recommended to be further tested preclinically and clinically for proposed activity against COVID-19. They may be tested either alone or in combination. This work may clarify and approve not only the safety of ARBs used by a large group of patients worldwide but also its possible effectiveness against the COVID-19 virus either as a prophylactic or treatment option. Besides, the results may clarify greatly the SAR required for M pro targeting, and facilitate the introduction of future new effective candidates against COVID-19.

A. Al-Karmalawy: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

R. Alnajjar, A. Mostafa and A. Kandeil: Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Abbreviations: "CC 50 " half-maximal cytotoxic concentration; "IC 50 " half maximal inhibitory concentration; "SI" Safety index.

The authors declare no conflict of interest.

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2020.e05641.

Department of virology , biological and pathological center , centre hospitalier

COVID-19) Pandemic

The rise of new coronavirus infection-(COVID-19): a recent update

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Clinical Implications of Basic Research How to Discover

Therapeutic switching: a new strategic approach to enhance R&D productivity

The Drug Repurposing Hub: a nextgeneration drug library and information resource

Tanshinone IIA Synergistically Enhances the Antitumor Activity of Doxorubicin by Interfering with the PI3K/AKT/mTOR Pathway and Inhibition of Topoisomerase II : in Vitro and Molecular Docking Studies y

Empagli Fl Ozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin : in Vitro and Molecular Docking Studies

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Al-karmalawy, Molecular Docking Reveals the Potential of Cleome Amblyocarpa Isolated Compounds to Inhibit COVID-19 Virus Main Protease

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?

An interactive web-based dashboard to track COVID-19 in real time

The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease

COVID-19 and renin angiotensin blockers: current evidence and recommendations

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19

Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Molecular Operating Environment (MOE)

Desmond Molecular Dynamics System

Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

RosettaLigand docking with full ligand and receptor flexibility

The performance of current methods in ligand-protein docking

Molecular Modelling of Mebendazole Polymorphs as a Potential Colchicine Binding Site Inhibitor

OPLS3 : A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins

Simulation of Activation Free Energies in Molecular Systems I

Comparison of Simple Potential Functions for Simulating Liquid Water Comparison of Simple Potential Functions for Simulating Liquid Water

Desmond Molecular Dynamics System

Nos e -hoover chains: the canonical ensemble via continuous dynamics Nose-Hoover chains: the canonical ensemble via continuous dynamics

Constant pressure molecular dynamics algorithms

Bicyclo[1.1.1]Pentane as phenyl substituent in atorvastatin drug to improve physicochemical properties: drug-likeness, DFT, pharmacokinetics, docking, and molecular dynamic simulation

Research article of the essential oil of Nepeta Deflersiana Schweinf growing in KSA

Rapid Colorimetric Assay for Cellular Growth and Survival : Application to Proliferation and Cytotoxicity Assays

Crystal Violet Assay for Determining Viability of Cultured Cells